210644-62-5

Usage

Uses

Used in Pharmaceutical Industry:
SU 6668 is used as a PDGFR Tyrosine Kinase Inhibitor VI for its potent ATP-competitive inhibition against tyrosine kinases, which plays a crucial role in the development and progression of various cancers.
Used in Cancer Research:
SU 6668 is used as a research tool for studying the role of receptor tyrosine kinases in cancer cell growth, angiogenesis, and tumor development. Its ability to inhibit multiple kinases makes it a valuable compound in understanding the complex signaling pathways involved in cancer progression.
Used in Drug Development:
SU 6668 is used as a lead compound in the development of novel therapeutic agents targeting receptor tyrosine kinases and other ser/thr kinases, with potential applications in the treatment of various types of cancer.
Used in Angiogenesis Inhibition:
SU 6668 is used as an inhibitor of angiogenesis, the process through which new blood vessels form from pre-existing ones. This property makes it a potential therapeutic agent for conditions where inhibition of blood vessel growth is desired, such as in cancer treatment.
Used in Tumor Development Studies:
SU 6668 is used to study the role of PDGF/VEGF/bFGF-mediated signaling in tumor development, providing insights into the molecular mechanisms underlying cancer progression and the potential for targeted therapeutic intervention.

InChI:InChI=1/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-

Upstream product

• 59-48-3 2-oxoindole 
• 1133-96-6 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)-propionic acid 
• 17266-65-8 ethyl 4,6-dioxo-5-methylheptanoate 
• 54474-50-9 2,4-dimethyl-3-pyrrolepropanoic acid 
• 54278-10-3 ethyl 5-(ethoxycarbonyl)-2,4-dimethyl-1H-pyrrole-3-propanoate 
• 54474-51-0 methyl 2,4-dimethyl-3-pyrrolepropionate 
• 13219-76-6 4-<2-(methoxycarbonyl)ethyl>-3,5-dimethylpyrrole-2-carboxylic acid 
• 20303-31-5 benzyl 4-(2-methoxycarbonylethyl)-3,5-dimethylpyrrole-2-carboxylate 
• 18818-25-2 methyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoate 
• 16132-20-0 tert-butyl 3,5-dimethyl-4-(2-methoxycarbonylethyl)-1H-pyrrole-2-carboxylate 
• 123-75-1 pyrrolidine 

Relevant academic research and scientific papers

DIHYDROINDOLE DERIVATIVES USEFUL IN PARKINSON'S DISEASE

The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis

The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis,

Syntheses and properties of benzodipyrrinones

2,3-Benzannelated dipyrrinone analogs (1 and 2) of xanthobilirubic acid (3) are prepared by base-catalyzed condensation of isoindolinone (5) and indolin-2-one (6) respectively, with methyl 3-(2-formyl-3,5-dimethyl-1H-pyrrol-4-yl)propanoate (4). Nuclear Overhauser effect H-nmr studies indicate that both 1 and 2 adopt preferentially a syn-Z configuration. The former forms a hydrogen-bonded homodimer in nonpolar solvents; the latter is intramolecularly hydrogen bonded.

Pyrrole substituted 2-indolinone protein kinase inhibitors

The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Design, synthesis, and evaluations of substituted 3-[(3- or 4- carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases

Receptor tyrosine kinases (RTKs) have been implicated as therapeutic targets for the treatment of human diseases including cancers, inflammatory diseases, cardiovascular diseases including arterial restenosis, and fibrotic diseases of the lung, liver, and kidney. Three classes of 3-substituted indolin-2-ones containing propionic acid functionality attached to the pyrrole ring at the C-3 position of the core have been identified as catalytic inhibitors of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) RTKs. Some of the compounds were found to inhibit the tyrosine kinase activity associated with isolated vascular endothelial growth factor receptor 2 (VEGF-R2) [fetal liver tyrosine kinase 1 (Flk-1)/kinase insert domain- containing receptor (KDR)], fibroblast growth factor receptor (FGF-R), and platelet-derived growth factor receptor (PDGF-R) tyrosine kinase with IC50 values at nanomolar level. Thus, compound 1 showed inhibition against VEGF-R2 (Flk-1/KDR) and FGF-R1 tyrosine kinase activity with IC50 values of 20 and 30 nM, respectively, while compound 16f inhibited the PDGF-R tyrosine kinase activity with IC50 value of 10 nM. Structural models and structure-activity relationship analysis of these compounds for the target receptors are discussed. The cellular activities of these compounds were profiled using cellular proliferation assays as measured by bromodeoxyuridine (BrdU) incorporation. Specific and potent inhibition of cell growth was observed for some of these compounds. These data provide evidence that these compounds can be used to inhibit the function of these target receptors.